Actively Recruiting
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
Led by University of Nevada, Las Vegas · Updated on 2026-04-15
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the relationship between stroke volume measurements taken by transthoracic echocardiography and a noninvasive bioreactance-based cardiac output monitoring device called Cheetah NICOM in adults with shock. This observational study aims to determine how well these two methods agree in critically ill patients, helping to understand their reliability and usefulness without changing patient treatment. The research is sponsored by the University of Nevada, Las Vegas. Participants are adults diagnosed with shock who will have their stroke volume measured twice: once before and once after a passive leg raising test. Both echocardiography and the Cheetah NICOM device will be used to gather these measurements. No treatments or interventions will be given as part of the study, and all medical care decisions will be made by the regular care team. The study is prospective and observational, focusing on measurement comparison. During the study, stroke volume readings will be recorded within one hour of enrollment, including before and after the passive leg raising procedure. The primary outcome is the correlation between the two measurement methods in terms of absolute stroke volume values and changes. There will be no experimental treatments, and safety monitoring is managed by the usual clinical care. Participation involves monitoring and data collection only, with no additional interventions or follow-up beyond the initial assessment.
CONDITIONS
Brief Title
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age ≥ 18 years
- Clinical diagnosis of shock by the treating ICU physician (e.g., hypotension requiring vasopressors or signs of organ hypoperfusion)
- Ability to provide informed consent or have a legally authorized representative
- Enrollment within 24 hours of ICU admission
You will not qualify if you...
- Pregnancy
- Severe aortic valve disease or dynamic left ventricular outflow tract obstruction
- Morbid obesity (BMI > 40) preventing accurate echocardiographic imaging
- Cardiac arrhythmias affecting stroke volume measurements (e.g., atrial fibrillation with rapid ventricular response)
- Implanted cardiac assist devices such as LVAD or pacemaker dependency
- Imminent death or decision for comfort care only
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment and consent
Duration - Within 1 hour of enrollment
Participants have stroke volume measured using transthoracic echocardiography and bioreactance-based monitoring (Cheetah NICOM) before and after passive leg raising.
1 in-person assessment visit
Duration - Up to ICU discharge
Participants are observed without therapeutic intervention while clinical decisions remain under the discretion of the treating medical team.
No additional study visits; routine clinical care continues
Trial Site Locations
Total: 1 location
1
University Medical Center Southern Nevada
Las Vegas, Nevada, United States, 89102
Actively Recruiting
Research Team
M
Mutsumi J Kioka, Medical Doctor
O
Office of Research Integrity Human Subjects UNLV
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here